Cardiac biomarkers in heart failure

被引:46
作者
Liquori, Michael E. [1 ]
Christenson, Robert H. [2 ]
Collinson, Paul O. [3 ]
deFilippi, Christopher R. [4 ]
机构
[1] Univ Maryland, Sch Med, Dept Internal Med, Baltimore, MD 21201 USA
[2] Univ Maryland, Sch Med, Dept Pathol, Baltimore, MD 21201 USA
[3] Univ London St Georges Hosp, London SW17 0QT, England
[4] Univ Maryland, Sch Med, Dept Med, Baltimore, MD 21201 USA
关键词
Heart failure; Biomarkers; Cardiac; Troponin; Natriuretic peptide; C-REACTIVE-PROTEIN; BRAIN NATRIURETIC PEPTIDE; GROWTH-DIFFERENTIATION FACTOR-15; MIDREGIONAL PRO-ADRENOMEDULLIN; RECEPTOR FAMILY-MEMBER; TUMOR-NECROSIS-FACTOR; TERMINAL PROVASOPRESSIN COPEPTIN; PLASMA MYELOPEROXIDASE LEVELS; LEFT-VENTRICULAR DYSFUNCTION; HIGH-SENSITIVITY TROPONIN;
D O I
10.1016/j.clinbiochem.2014.01.032
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: Heart failure is a syndrome characterized by the inability of the heart to meet the body's circulatory demands. Heart failure is a growing health issue worldwide and the prevalence of heart failure is expected to rise as populations age. Therapies and interventions for a variety of cardiac conditions continue to advance and biomarkers will play an increasing role in patient management. Methods: This is a review of the clinical research in blood based biomarkers for diagnosis, prognosis and therapeutic guidance of heart failure. The focus of this review is biomarkers that are currently available for clinical measurement, and their current and potential for applications for managing heart failure patients. Results: The various biologic pathways and physiologic processes of heart failure biomarkers represent a host of different including inflammation, remodeling, strain, neurohormonal activation, metabolism and cardiac myocyte injury. The clinical characteristics and applications of each heart failure biomarker are discussed. Conclusion: As populations age and effective treatments and interventions for coronary artery disease improve, heart failure will increase in incidence and prevalence. Blood biomarkers will play an increasing role in the early diagnosis, therapeutic monitoring and management of heart failure patients in the future. (C) 2014 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:327 / 337
页数:11
相关论文
共 151 条
[1]   Prognostic value of plasma midregional pro-adrenomedullin and C-terminal-pro-endothelin-1 in chronic heart failure outpatients [J].
Adlbrecht, Christopher ;
Huelsmann, Martin ;
Strunk, Guido ;
Berger, Rudolf ;
Moertl, Deddo ;
Struck, Joachim ;
Morgenthaler, Nils G. ;
Bergmann, Andreas ;
Jakowitsch, Johannes ;
Maurer, Gerald ;
Lang, Irene M. ;
Pacher, Richard .
EUROPEAN JOURNAL OF HEART FAILURE, 2009, 11 (04) :361-366
[2]   Association of Copeptin and N-Terminal proBNP Concentrations With Risk of Cardiovascular Death in Older Patients With Symptoms of Heart Failure [J].
Alehagen, Urban ;
Dahlstroem, Ulf ;
Rehfeld, Jens F. ;
Goetze, Jens P. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2011, 305 (20) :2088-2095
[3]   C-reactive protein as a predictor of improvement and readmission in heart failure [J].
Alonso-Martínez, JL ;
Llorente-Diez, B ;
Echegaray-Agara, M ;
Olaz-Preciado, F ;
Urbieta-Echezarreta, M ;
González-Arencibia, C .
EUROPEAN JOURNAL OF HEART FAILURE, 2002, 4 (03) :331-336
[4]   Serial Measurement of Growth-Differentiation Factor-15 in Heart Failure Relation to Disease Severity and Prognosis in the Valsartan Heart Failure Trial [J].
Anand, Inder S. ;
Kempf, Tibor ;
Rector, Thomas S. ;
Tapken, Heike ;
Allhoff, Tim ;
Jantzen, Franziska ;
Kuskowski, Michael ;
Cohn, Jay N. ;
Drexler, Helmut ;
Wollert, Kai C. .
CIRCULATION, 2010, 122 (14) :1387-+
[5]   How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH [J].
Anker, SD ;
Coats, AJS .
INTERNATIONAL JOURNAL OF CARDIOLOGY, 2002, 86 (2-3) :123-130
[6]  
[Anonymous], CARDIAC BIOMARKERS C
[7]  
[Anonymous], HARRISONS PRINCIPLES
[8]  
[Anonymous], CIRCULATION
[9]  
[Anonymous], CLIN CHALLENGES HEAR
[10]   Myeloperoxidase and plasminogen activator inhibitor 1 play a central role in ventricular remodeling after myocardial infarction [J].
Askari, AT ;
Brennan, ML ;
Zhou, XR ;
Drinko, J ;
Morehead, A ;
Thomas, JD ;
Topol, EJ ;
Hazen, SL ;
Penn, MS .
JOURNAL OF EXPERIMENTAL MEDICINE, 2003, 197 (05) :615-624